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Abstract
Background: Aldosterone-producing adrenocortical carcinoma is a rare malignancy, which is usually diagnosed by
histopathological examination of the excised tumor. In inoperable cases, aldosterone-producing ACC diagnosed by
immunohistochemical staining of the metastatic tumor for Cytochrome P450 (CYP) 11β has not previously been
reported and even in that case staining for adrenocortical-specific adrenal 4 binding protein/steroidogenic factor1
(Ad4BP/SF1) and steroidogenic enzymes has not been reported.
Case presentation: We report the case of a 67-year-old Japanese woman with aldosterone-producing
adrenocortical carcinoma. Laboratory findings showed severe hypopotassemia. Endocrinological examination
revealed an increased plasma aldosterone concentration and suppressed plasma renin activity. Plasma
dehydroepiandrosterone sulfate (DHEA-S) was elevated. Diurnal variation in serum cortisol was lost and
administration of 1 mg and 8 mg dexamethasone did not suppress serum cortisol levels. From the 24-h urine
collection sample, urine aldosterone and urine cortisol levels were greatly increased. Therefore, autonomous excess
production was observed for the three adrenal cortex hormones. Abdominal computed tomography and magnetic
resonance imaging showed a right adrenal tumor and a huge liver tumor. Adrenocortical carcinoma with
metastatic liver cancer was strongly suggested, however surgery could not be considered due to stage IV disease:
the liver tumor was too large and cardiac ultrasonography indicated that her cardiac function was poor. Therefore,
a liver biopsy was taken to properly determine the diagnosis. Immunohistochemical stains for Ad4BP/SF1 and
steroidogenic enzymes were positive. Ad4BP/SF-1 was originally identified as a steroidogenic, tissue-specific
transcription factor implicated in the expression of the steroidogenic CYP gene encoding cytochrome P450s. Hence
we could diagnose the patient as having adrenocortical carcinoma with metastatic liver cancer.
Conclusion: This rare case had severe hypopotassemia accompanied with not only increased cortisol and DHEA-S
but also aldosterone. We reached the diagnosis of adrenocortical carcinoma with metastatic liver cancer based on
positive immunohistochemical staining of Ad4BP/SF1 in the liver biopsy specimen. We have reported the first case
of aldosterone-producing adrenocortical carcinoma diagnosed solely by immunohistochemical staining for
adrenocortical-specific Ad4BP/SF1 and steroidogenic enzymes in a metastatic liver tumor.
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Background
Adrenocortical carcinoma (ACC) is a rare malignancy
with an incidence of 1–2 per million people. ACC fol-
lows a heterogeneous clinical course and a variable but
generally poor prognosis [1–4]. Approximately 60 % of
ACCs are hormonally active, and glucocorticoids and/or
androgens are the steroids that are frequently over-
secreted. A rapidly progressive Cushing’s syndrome with
or without virilization is the most frequent manifest-
ation; estrogen or mineralocorticoid excess occurs in
10 % or fewer cases [1–3, 5]. ACC is usually diagnosed
by histopathological examination of the excised tumor.
In inoperable cases, aldosterone-producing ACC diag-
nosed by immunohistochemical staining of the meta-
static tumor for Cytochrome P450 (CYP) 11β has not
previously been reported and even in that case staining
for adrenocortical-specific adrenal 4 binding protein/
steroidogenic factor1 (Ad4BP/SF1) and steroidogenic
enzymes has not been reported.
Here we report the first case of aldosterone-producing
ACC diagnosed by immunohistochemical staining in
only the metastatic tumor to detect both Ad4BP/SF1
and steroidogenic enzymes.
Case presentation
A 67-year-old woman with a history of diabetes mellitus
and hypertension was referred to our hospital for evalu-
ation of hypopotassemia, a right adrenal tumor and a
huge liver tumor. She complained of dizziness and
weight loss. We suspected that she had ACC and meta-
static liver cancer. Physical examination showed thin
skin, hirsutism, hepatomegaly and mild leg edema. She
did not have a cushingoid appearance with manifesta-
tions such as a moon face, central obesity and buffalo
hump.
Laboratory findings (Table 1) showed severe hypopo-
tassemia (K: 1.2 mmol/l), leukocytosis and liver damage.
Carcinoembryonic antigen (CEA), carbohydrate antigen
19–9 (CA19-9) and protein induced by vitamin K ab-
sence or antagonist-II (PIVKA-II)—which is a hepatocel-
lular carcinoma marker—were elevated.
Endocrinological examination (Table 2) revealed an in-
creased plasma aldosterone concentration (PAC:
2040.0 pg/ml) and suppressed plasma renin activity
(PRA: 0.3 ng/ml/h). Plasma DHEA-S was elevated
(294 μg/dl). Diurnal variation in serum cortisol was lost.
Fasting plasma levels of adrenocorticotropic hormone
(ACTH) and cortisol were less than 2.1 pg/ml (7.2–63.3)
and 27.7 μg/dl (4.0–18.2), respectively, and administra-
tion of 1 mg and 8 mg dexamethasone did not suppress
serum cortisol levels. In addition, 24-h urine was col-
lected, and the urinary aldosterone level was 230.0 μg/
day (>10) and the urinary cortisol level was 477.0 μg/day
(11.2–80.3).
Autonomous excess production was demonstrated for
the three adrenal cortex hormones (aldosterone, cortisol
and DHEA-S). Abdominal computed tomography (CT)
showed an internal heterogeneous right adrenal tumor
(6 cm in diameter) with calcification as well as a huge
liver tumor (14 cm in diameter) with internal necrosis
(Fig. 1).
As a result of laboratory findings, endocrinological
examination and abdominal enhanced CT and MRI, an
ACC with widespread metastatic liver cancer was
strongly suggested. We wanted to excise the adrenal
tumor including the liver tumor for diagnosis and treat-
ment. But this case could not be considered for surgery
because of stage IV disease: the liver tumor was too
large and cardiac ultrasonography indicated that her car-
diac function was poor (ejection fraction: 32 %). There-
fore a liver biopsy was taken to determine the diagnosis.
At histopathological examination, hematoxylin and eosin
(HE) staining indicated a diagnosis of carcinoma. Hep-
atocyte paraffin 1 staining was negative in this case, so
this tumor was not a hepatocellular carcinoma. Immu-
nohistochemical staining for Ad4BP/SF1 and steroido-
genic enzymes were positive. P450scc, 3β-HSD, P450c21,
P450c17 and DHEA-ST were all positive (Figs. 2 and 3).
Table 1 Laboratory findings
Urine Biochemistry
Protein (2+) AST 107 IU/l
Glucose (+) ALT 68 IU/l
Ketone (−) LDH 1105 IU/l
U-UN 0.119 mg/dl ChE 3479 IU/l
U-Cr 11.3 mg/dl T-Bil 1.1 mg/dl
U-Na 28 mmol/l ALP 636 lU/l
U-K 15.3 mmol/l γ-GT 344 IU/l
U-Cl 21 mmol/l TP 6.6 g/dl
Alb 4.0 g/dl
Blood cell count UN 24 mg/dl
WBC 16300/μl Cr 0.8 mg/dl
Neutrophil 84.6 % UA 4.4 mg/dl
Lymphocyte 9.7 % Na 145 mmol/l
Monocyte 5.5 % K 1.2 mmol/l
Eosinophil 0.1 % Cl 80 mmol/l
Basophil 0.1 % Ca 8.8 mg/dl
RBC 4.59 × 106/μl Plasma glucose 159 mg/dl
Hemoglobin 14.4 g/dl HbA1c 6.0 %
Hematocrit 43.5 % CRP 6.2 mg/dl
Platelet 36.7 × 104/μl
Tumor markers
CEA 17.1 ng/ml (5.8>) AFP 4 ng/ml (10>)
CA19-9 294 U/ml (37>) PIVKAII 183 mAU/ml (40>)
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Therefore, we finally reached a diagnosis of ACC with
metastatic liver cancer.
Her prominent hypopotassium values improved (K
3.9 mmol/l) with administration of trilostane (240 mg/day).
She was also administered mitotane (1.5 g/day) with
dexamethasone.
Reductions in cortisol and aldosterone levels were
gradually achieved (cortisol 23.5 μg/dl and PAC
246.0 pg/ml). However, at her request, she was trans-
ferred to another hospital where she died 3 months
later.
Discussion
Here we reported the first case of aldosterone-producing
ACC diagnosed by immunohistochemical staining in
only the metastatic tumor to detect both Ad4BP/SF1
and steroidogenic enzymes.
The present case demonstrated severe hypopotassemia
accompanied with not only increased cortisol and
DHEA-S but also aldosterone. Approximately 60 % of
ACCs are hormonally active, and glucocorticoids and/or
androgens are frequently over-secreted. Mineralocortic-
oid excess is very rare [1–3, 5].
Generally, there is a high suspicious for malignancy
if adrenal tumors are larger than 6 cm [6]. Large clin-
ically asymptomatic adrenal masses are treated sur-
gically and then diagnosed by histopathological
examination. A microscopic diagnostic score (Weiss
score) is the most commonly used tool [7]. Surgery
was not considered in this case because disease was
classified as stage IV [3]: the liver tumor was too
large and cardiac ultrasonography indicated that her
cardiac function was poor. Local invasion, tumor ex-
tension into the inferior vena cava as well as lymph
nodes or other metastases (lung and liver) are often
found in advanced ACC [3].
After various medical tests, ACC with widespread
metastatic liver cancer was strongly suspected, and a
liver biopsy was performed to rule out hepatocellular
carcinoma due to increased PIVKA-II score. With HE
staining, tumor cells showed large conspicuous nuclei,
nuclear atypicality, and acidophilic cytoplasm that had a
cord-like architectural pattern and alveolar structure.
This tumor was diagnosed as a carcinoma. Hepatocyte
paraffin 1 staining was negative, thus indicating that this
case did not have hepatocellular carcinoma. We applied
Table 2 Endocrinological examination
Normal range
Hormonal profile
Serum ACTH (pg/ml) < 2.1 7.2–63.3
Serum cortisol (μg/dl) 27.7 4.0–18.3
Plasma renin activity (ng/ml/hr) 0.3 0.3–2.9
Plasma aldosterone concentration (pg/ml) 2040 140–1030
Serum DHEA-S (μg/dl) 294 12–133
Serum 11-OHCS (μg/dl) 566.0 7.0–23.0
Urinary free cortisol (μg/24 hr) 477.0 11.2–80.3
Urinary free aldosterone (μg/24 hr) 230.0 < 10
Diurnal variation of plasma ACTH, cortisol levels
9:00 16:00 23:00
Serum ACTH (pg/ml) < 2.1 < 2.1 < 2.1
Serum cortisol (μg/dl) 43.6 47.7 42.6
Dexamethasone suppression test 1 mg 8 mg
Serum ACTH (pg/ml) < 2.1 < 2.1
Serum cortisol (μg/dl) 36.0 39.1
Fig. 1 Abdominal dynamic computed tomography. Abdominal dynamic computed tomography shows a huge liver tumor (14 cm in diameter)
and right adrenal tumor (6 cm in diameter). a slice of liver tumor; b slice of right adrenal tumor
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immunohistochemical staining for Ad4BP/SF1 and ste-
roidogenic enzymes to distinguish whether cells in this
tumor were those of ACC. Ad4BP/SF-1 was originally
identified as a steroidogenic, tissue-specific transcrip-
tion factor implicated in the expression of the steroido-
genic CYP gene encoding cytochrome P450s [8]. An
immunohistochemical evaluation of Ad4BP/SF-1 can
aid in this differential diagnosis because nuclear immu-
noreactivity for this transcription factor is relatively spe-
cific to steroid-producing cells. It has been reported that
application of Ad4BP/SF-1 immunohistochemistry can
greatly contribute to the differential diagnosis of ACC
from other malignancies both at primary and metastatic
sites [9]. In addition, it has been reported that Ad4BP/
SF-1 is a very useful immunohistochemical marker in
diagnosing the origin of metastatic sites of ACC [10].
This case had positive immunoreactivity for Ad4BP/
SF1. Immunohistochemical staining for steroidogenic
enzymes also showed positive reactivity. P450scc, 3β-HSD,
P450c21, P450c17 and DHEA-ST were all positive. There-
fore we diagnosed that this patient had ACC with meta-
static liver cancer.
Fig. 2 Histopathological diagnosis by examination of liver biopsy specimen. a Tumor cells show large conspicuous nuclei, nuclear atypicality, and
acidophilic cytoplasm. Cells had a cord-like architectural pattern and alveolar structure (HE staining, original magnification × 400); b Normal hepatocytes
(HE, ×400); c These tumor cells are undyed; d Normal hepatocytes became stained (C, D: Hepatocyte paraffin 1 staining, ×400); e-i Immunohistochemical
stainings showed positive reactivity (E: Ad4BP/SF1, ×40; F: Ad4BP/SF1, ×400; G: 3β-HSD, ×40; H: P450c21, ×40; I: Inhibinα, ×40). Black arrow: Ad4BP/SF1 was
stained in a nucleus. White arrow: steroidogenic enzymes was stained in cytoplasm
Fig. 3 Steroid hormone biosynthesis pathway. We applied immunohistochemical staining for P450scc, 3β-HSD, P450c21, P450c17 and DHEA-ST
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We identified a case of distant recurrence of ACC
after adrenalectomy that was diagnosed by immunohis-
tochemical staining for steroidogenic enzymes in a lung
metastatic tumor [11]. An ACC case with pulmonary
metastasis diagnosed by a pleural biopsy was also reported
[12]. However, in that pulmonary metastasis report, im-
munohistochemical staining for Ad4BP/SF1 and steroido-
genic enzymes was not performed.
We acknowledge several limitations in our report.
First, we could not use immunohistochemical staining
to examine the original adrenal tumor for Ad4BP/SF1
and steroidogenic enzymes. Second, there is no evi-
dence that this tumor produced aldosterone, because
we could not apply immunohistochemical staining for
CYP11B1 and CYP11B2 in a metastatic tumor at that
time. Despite these limitations, we strongly suspected
that these tumors produced aldosterone because PAC
increased significantly as a result of endocrinological
examination.
Conclusion
Here, we report a rare case of ACC with severe hypopo-
tassemia accompanied not only increased cortisol and
DHEA-S but also aldosterone. We were successful in
diagnosing the patient as having ACC with metastatic
liver cancer based on positive immunohistochemical
staining of metastatic cancer for adrenocortical specific
Ad4BP/SF1 and steroidogenic enzymes.
Consent
Informed consent was obtained from the patient’s family
for publication of this case report and any accompanying
images.
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